A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation (ASH 2026) - Sep 26, 2026 - "Hany Elmariah (Stanford) presenting "New Standards in GVHD Prophylaxis: Towards a Future Without GVHD," which examines the latest advances in prophylactic strategies, including Orca-T, abatacept, and post-transplant cyclophosphamide (PTCy), and how these approaches are reshaping the standard of care...These include ruxolitinib and mesenchymal stromal cells (MSCs) for acute GVHD (with pediatric indications), as well as belumosudil, ruxolitinib, and axatilimab for chronic GVHD, and how they are improving outcomes for patients with steroid-refractory disease...Holtan's talk, "A Donor for All: Increasing Access and Improving Outcomes," which addresses expanding donor options through mismatched unrelated donor (MMURD), haploidentical, and cord blood transplantation, emphasizing the data supporting broader access and equitable outcomes across donor types. These presentations chart a bold trajectory for the field, illuminating how..."
Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation
|